NIMI
PBYI icon

Natixis Investment Managers International’s Puma Biotechnology PBYI Stock Holding History

Natixis Investment Managers International’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-85
Closed -$6K – 446
2015
Q3 		$6K Buy
+85
New +$8.04K ﹤0.01% 428

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis Investment Managers International's PBYI Position: Q4 2015 in Review

Natixis Investment Managers International sold out of Puma Biotechnology (PBYI) in Q4 2015, closing a stake of 85 shares — an estimated $6K sold.

Natixis Investment Managers International first reported a position in PBYI in Q3 2015 and held it in 1 quarter. The position peaked at $6K in Q3 2015. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2015.

  • Natixis Investment Managers International reported no remaining Puma Biotechnology position as of Q4 2015 after selling out during the quarter.
  • Natixis Investment Managers International sold 85 Puma Biotechnology shares in Q4 2015, an estimated $6K.
  • Natixis Investment Managers International first reported a position in Puma Biotechnology in Q3 2015 and held it in 1 quarter.
  • Natixis Investment Managers International's Puma Biotechnology position peaked at $6K in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2015.

Based on Natixis Investment Managers International's 13F filing for Q4 2015, filed 16 Feb 2016.